Table.

Previous and Present Cases of New-onset or Relapse of AOSD Following COVID-19 Vaccination.

Case no.		Age (y)/sex	Vaccine		Days from vaccination to new-onset or relapse of AOSD	With (+) or without (-) MAS	Treatment	Response	Reference
			Type	Dose number
	New-onset
1		36/M	Vector	1st	1	-	mPSL pulse, anakinra 100 mg/day	Improved	13
2		45/F	mRNA	2nd	5	-	PSL 60 mg/day	Improved	14
3		43/M	mRNA	2nd	10	-	mPSL pulse, PSL 60 mg/day	Improved	15
4		56/F	mRNA	2nd	7	-	PSL 60 mg/day	Improved	15
5		36/F	mRNA	1st	10	-	mPSL pulse, tocilizumab 8 mg/kg, iv	Improved	16
6		22/M	mRNA	1st	13	+	mPSL pulse, IVIg 2 g/kg, PSL 100 mg/	Improved	17
							day, anakinra 100 mg/day
7		53/M	Vector	1st	56	-	PSL 60 mg/day	Improved	18
8		20/F	Vector	1st	10	-	Naproxen	Improved	19
9		47/F	Vector	1st	21	-	PSL 0.5 mg/kg, MTX, tocilizumab 162	Improved	19
							mg, sc
10		35/F	Vector	1st	90	+	mPSL pulse, IVIg 2 g/kg, tocilizumab 8	Improved	19
							mg/kg, iv
11		59/F	mRNA	1st	7	+	PSL 50 mg/day, tocilizumab 8 mg/kg, iv,	Improved	Our case 1
							mPSL pulse, cyclosporin
12		77/F	mRNA	2nd	42	+	mPSL pulse, PSL 60 mg/day, mPSL pulse, cyclosporin, tocilizumab 8 mg/kg, iv	Improved	Our case 2
13		35/M	mRNA	1st	24	-	PSL 40 mg/day	Improved	Our case 3
	Relapse
14		34/F	Vector	1st	7	-	PSL 50 mg/day, mPSL pulse, etanercept	Improved	20
							50 mg, MTX 10 mg/week, PSL 75 mg/day,
							tocilizumab 8 mg/kg, iv
15		20/F	mRNA	1st	6	+	mPSL pulse, IVIg, anakinra 300 mg/day,	Improved	21
							ciclosporin
16		37/F	mRNA	2nd	A few days	-	PSL 15 mg/day, tocilizumab 162 mg, sc	Improved	22
17		49/F	mRNA	1st	4	+	Tocilizumab 400 mg, iv, mPSL pulse,	Improved	23
							MTX

iv: intravenous, IVIg: intravenous immunoglobulin, MAS: macrophage activation syndrome, mPSL: methylprednisolone, mRNA: messenger ribonucleic acid, MTX: methotrexate, PSL: prednisolone, sc: subcutaneous